01 / 20

Chronic Psychiatric
Disease Management

A longitudinal approach to maintenance pharmacotherapy, monitoring, and relapse prevention in chronic mental illness.

USMLE Step 3

What Is Chronic Management?

Chronic psychiatric disease management is the long-term, outpatient stewardship of conditions like major depressive disorder, bipolar disorder, and schizophrenia. Step 3 emphasizes the continuity-of-care phase, not just acute stabilization.

The Three Treatment Phases

Acute 6-12 weeks Continuation 4-9 months Maintenance 1+ years Goal: prevent relapse and recurrence

The Adherence Problem

Up to 50% of psychiatric patients are non-adherent to maintenance medication. Adherence is the single largest modifiable driver of relapse.

Core Rule: Continue What Worked

1
Effective dose continues. The remission dose is the maintenance dose for depression.
2
Duration depends on episodes. First episode MDD: 6-12 months. Recurrent: years to lifelong.
3
Monitor, don't taper prematurely. Premature discontinuation drives recurrence.

Deciding Treatment Duration

For MDD, the recommended maintenance length increases with the number of prior episodes. A useful framing:

1 Episode
Continue 6-12 months after remission, then consider taper.
2 Episodes
Consider 1-3 years or longer if risk factors present.
3+ Episodes
Indefinite maintenance is strongly recommended.

Relapse vs. Side Effect

A returning symptom is not always relapse. Distinguish a true return of illness from a medication adverse effect or withdrawal.

Relapse
Original symptom cluster returns; often follows dose reduction or non-adherence. Treat by reoptimizing therapy.
Adverse Effect
New symptom tied to drug pharmacology (e.g., weight gain, tremor). Manage by adjusting or switching agent.

A Step-by-Step Approach

1
Confirm remission. Use validated scales (PHQ-9, YMRS) to verify the patient is stable.
2
Assess adherence first for any worsening. Ask non-judgmentally; consider serum levels for lithium or valproate.
3
Order indicated monitoring. Match labs to the drug (see monitoring slide).
4
Adjust, don't abandon. Optimize the current regimen before switching.

Drug-Specific Monitoring

Chronic agents require scheduled labs. Memorize these high-yield pairings:

Lithium's Narrow Therapeutic Window

Serum lithium (mEq/L) Subtherapeutic Therapeutic
\(0.6 - 1.2\)
Toxic
\(> 1.5\)
\(0.6\)
\(1.2\)

Worked Example: MDD Maintenance

A 34-year-old woman with her first episode of MDD has been in remission for 4 weeks on sertraline 100 mg. She asks how long to continue.

Worked Example: Bipolar Stability

A 45-year-old man with bipolar I has been stable on lithium for 2 years. Routine labs show TSH 9.0 and a level of \(0.9 \, \text{mEq/L}\).

Worked Example: Worsening Psychosis

A 28-year-old with schizophrenia, stable on risperidone, returns with returning auditory hallucinations. He admits to missing doses for two weeks.

Common Mistakes

✕ Lowering the dose
Reducing an effective dose during maintenance triggers relapse. Keep the remission dose.
✕ Stopping for side effects
Manage adverse effects with adjuncts (e.g., levothyroxine) rather than abandoning a working drug.
✕ Ignoring adherence
Always assess adherence before declaring treatment failure or escalating therapy.

Monitoring Summary

Key Monitoring Maintenance Note
LithiumLevel, TSH, renalAvoid NSAIDs, thiazides
ValproateLevel, LFTs, CBCTeratogenic; avoid pregnancy
Atypical antipsychoticGlucose, lipids, weightMetabolic syndrome risk
SSRI (MDD)Mood, suicidalityContinue effective dose

Question 1 of 5

A 30-year-old woman with a first episode of MDD reaches remission on fluoxetine 20 mg. What is the best maintenance plan?

Question 2 of 5

A bipolar patient on long-term lithium develops fatigue. Labs: TSH 11, lithium level \(0.8 \, \text{mEq/L}\). Best next step?

Question 3 of 5

A patient with three prior episodes of MDD is now in remission. Recommended maintenance duration?

Question 4 of 5

A schizophrenia patient stable on risperidone develops returning hallucinations after admitting to missed doses. Best management?

Question 5 of 5

Which medication change most increases the risk of lithium toxicity in a stable patient?